{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:10:51Z","timestamp":1790277051100,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.biomaterials.2024.122586","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T06:34:08Z","timestamp":1714458848000},"page":"122586","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Co-delivery of Plinabulin and Tirapazamine boosts anti-tumor efficacy by simultaneously destroying tumor blood vessels and killing tumor cells"],"prefix":"10.1016","volume":"309","author":[{"given":"Jianlin","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4726-4305","authenticated-orcid":false,"given":"Zhaohui","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biomaterials.2024.122586_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"Ca-Cancer J. Clin."},{"key":"10.1016\/j.biomaterials.2024.122586_bib2","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","article-title":"Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics","volume":"10","author":"Anand","year":"2023","journal-title":"Genes Dis"},{"key":"10.1016\/j.biomaterials.2024.122586_bib3","doi-asserted-by":"crossref","first-page":"669","DOI":"10.3390\/cancers13040669","article-title":"Drug combination in cancer treatment-from cocktails to conjugated combinations","volume":"13","author":"Gilad","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.biomaterials.2024.122586_bib4","article-title":"Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer","volume":"4","author":"Ferrara","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.biomaterials.2024.122586_bib5","article-title":"Clinical trial designs for evaluating and exploiting cancer evolution","volume":"118","author":"Garces","year":"2023","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.biomaterials.2024.122586_bib6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/cpt.3085","article-title":"Oncology combination dose-finding study design for targeted and immuno-oncology therapies","volume":"115","author":"Zhou","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biomaterials.2024.122586_bib7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41573-022-00615-z","article-title":"Rational combinations of targeted cancer therapies: background, advances and challenges","volume":"22","author":"Jin","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biomaterials.2024.122586_bib8","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1039\/D3BM01858J","article-title":"Hindering the unlimited proliferation of tumor cells synergizes with destroying tumor blood vessels for effective cancer treatment","volume":"12","author":"Liu","year":"2024","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.biomaterials.2024.122586_bib9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biomaterials.2024.122586_bib10","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s13402-021-00602-3","article-title":"Angiogenesis as a hallmark of solid tumors-clinical perspectives","volume":"44","author":"Majidpoor","year":"2021","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.biomaterials.2024.122586_bib11","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1021\/acs.nanolett.1c00168","article-title":"Platelet-membrane-coated nanoparticles enable vascular disrupting agent combining anti-angiogenic drug for improved tumor vessel impairment","volume":"21","author":"Li","year":"2021","journal-title":"Nano Lett."},{"key":"10.1016\/j.biomaterials.2024.122586_bib12","article-title":"Tumor microenvironment remodeling-mediated sequential drug delivery potentiates treatment efficacy","author":"Xu","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.biomaterials.2024.122586_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2021.08.2127","article-title":"DUBLIN-3 (BPI-2358-103): a global phase (Ph) III trial with the plinabulin\/docetaxel (Plin\/Doc) combination vs. Doc in 2nd\/3rd line NSCLC patients (pts) with EGFR-wild type (wt) progressing on a prior platinum-based regimen","volume":"32","author":"Han","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biomaterials.2024.122586_bib14","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1158\/1078-0432.CCR-10-1096","article-title":"Phase 1 first-in-human trial of the vascular disrupting agent Plinabulin (NPI-2358) in patients with solid tumors or lymphomas","volume":"16","author":"Mita","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biomaterials.2024.122586_bib15","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s10637-011-9642-4","article-title":"Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel","volume":"30","author":"Millward","year":"2012","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.biomaterials.2024.122586_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.actbio.2021.07.015","article-title":"Tumor vasculature-targeting nanomedicines","volume":"134","author":"Zhang","year":"2021","journal-title":"Acta Biomater."},{"key":"10.1016\/j.biomaterials.2024.122586_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121736","article-title":"A self-activating nanoized vascular disrupting agent for selective anti-tumor therapy","volume":"288","author":"Xu","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.biomaterials.2024.122586_bib18","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41568-021-00378-6","article-title":"Cancer metabolism: looking forward","volume":"21","author":"Mart\u00ednez-Reyes","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biomaterials.2024.122586_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120537","article-title":"Activatable nanomedicine for overcoming hypoxia-induced resistance to chemotherapy and inhibiting tumor growth by inducing collaborative apoptosis and ferroptosis in solid tumors","volume":"268","author":"Fu","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.biomaterials.2024.122586_bib20","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.2147\/IJN.S362263","article-title":"Estrone-conjugated PEGylated liposome co-loaded paclitaxel and carboplatin improve anti-tumor efficacy in ovarian cancer and reduce acute toxicity of chemo-drugs","volume":"17","author":"Tang","year":"2022","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biomaterials.2024.122586_bib21","article-title":"Exploiting the acquired vulnerability of cisplatin-resistant tumors with a hypoxia-amplifying DNA repair-inhibiting (HYDRI) nanomedicine","volume":"7","author":"Chen","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.biomaterials.2024.122586_bib22","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.actbio.2023.06.017","article-title":"A bioresponsive diselenide-functionalized hydrogel with cascade catalytic activities for enhanced local starvation- and hypoxia-activated melanoma therapy","volume":"167","author":"Ding","year":"2023","journal-title":"Acta Biomater."},{"key":"10.1016\/j.biomaterials.2024.122586_bib23","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1200\/JCO.2009.27.4449","article-title":"Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck: a phase III trial of the trans-tasman radiation oncology group","volume":"28","author":"Rischin","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biomaterials.2024.122586_bib24","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1200\/JCO.2005.05.2878","article-title":"Prognostic significance of 18F-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine","volume":"24","author":"Rischin","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biomaterials.2024.122586_bib25","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/cjoc.202200065","article-title":"A novel vascular disrupting agents noncovalent polymeric nanomedicine: significantly increased antitumor therapeutic efficiency","volume":"40","author":"Lv","year":"2022","journal-title":"Chin. J. Chem."},{"key":"10.1016\/j.biomaterials.2024.122586_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202202834","article-title":"Deep-penetrating triple-responsive prodrug nanosensitizer actuates efficient chemoradiotherapy in pancreatic ductal adenocarcinoma models","volume":"18","author":"Tang","year":"2022","journal-title":"Small"},{"key":"10.1016\/j.biomaterials.2024.122586_bib27","doi-asserted-by":"crossref","first-page":"14693","DOI":"10.1021\/acsnano.2c05341","article-title":"Hypoxia-activated PEGylated paclitaxel prodrug nanoparticles for potentiated chemotherapy","volume":"16","author":"Hao","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.biomaterials.2024.122586_bib28","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1039\/C9CS00773C","article-title":"Molecular and nanoengineering approaches towards activatable cancer immunotherapy","volume":"49","author":"Zhang","year":"2020","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.biomaterials.2024.122586_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.120705","article-title":"Tuning the efficacy of esterase-activatable prodrug nanoparticles for the treatment of colorectal malignancies","volume":"270","author":"Wang","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.biomaterials.2024.122586_bib30","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s12274-021-3574-x","article-title":"Endogenous Fe2+ activated ROS nanoamplifier for esterase-responsive and photoacoustic imaging-monitored therapeutic improvement","volume":"15","author":"Xiang","year":"2022","journal-title":"Nano Res."},{"key":"10.1016\/j.biomaterials.2024.122586_bib31","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1080\/10717544.2019.1588424","article-title":"Application and design of esterase-responsive nanoparticles for cancer therapy","volume":"26","author":"Dong","year":"2019","journal-title":"Drug Deliv."},{"key":"10.1016\/j.biomaterials.2024.122586_bib32","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202207535","article-title":"Esterase-activated, pH-responsive, and genetically targetable nano-prodrug for cancer cell photo-ablation","volume":"19","author":"Liang","year":"2023","journal-title":"Small"},{"key":"10.1016\/j.biomaterials.2024.122586_bib33","doi-asserted-by":"crossref","DOI":"10.1093\/nsr\/nwae038","article-title":"Introducing urea into tirapazamine derivatives to enhance anticancer therapy","volume":"11","author":"Xu","year":"2024","journal-title":"Natl. Sci. Rev."},{"key":"10.1016\/j.biomaterials.2024.122586_bib34","doi-asserted-by":"crossref","first-page":"9274","DOI":"10.1002\/anie.202017088","article-title":"Monomer controlled switchable copolymerization: a feasible route for the functionalization of poly(lactide)","volume":"60","author":"Huang","year":"2021","journal-title":"Angew. Chem., Int. Ed."},{"key":"10.1016\/j.biomaterials.2024.122586_bib35","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s10637-011-9642-4","article-title":"Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel","volume":"30","author":"Millward","year":"2012","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.biomaterials.2024.122586_bib36","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/10408363.2021.2014781","article-title":"Von Willebrand factor and disease: a review for laboratory professionals","volume":"59","author":"Harris","year":"2022","journal-title":"Crit. Rev. Clin. Lab Sci."},{"key":"10.1016\/j.biomaterials.2024.122586_bib37","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1016\/j.immuni.2023.08.001","article-title":"Mechanotransduction via endothelial adhesion molecule CD31 initiates transmigration and reveals a role for VEGFR2 in diapedesis","volume":"56","author":"Fu","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.biomaterials.2024.122586_bib38","doi-asserted-by":"crossref","first-page":"6659","DOI":"10.1038\/s41467-023-41946-8","article-title":"Aromatized liposomes for sustained drug delivery","volume":"14","author":"Li","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biomaterials.2024.122586_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.119982","article-title":"Stepwise-activatable hypoxia triggered nanocarrier-based photodynamic therapy for effective synergistic bioreductive chemotherapy","volume":"245","author":"Ihsanullah","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.biomaterials.2024.122586_bib40","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1007\/s11426-022-1347-9","article-title":"Vascular disrupting agent-induced amplification of tumor targeting and prodrug activation boosts anti-tumor efficacy","volume":"65","author":"Hong","year":"2022","journal-title":"Sci. China Chem."},{"key":"10.1016\/j.biomaterials.2024.122586_bib41","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1007\/s11426-021-1168-4","article-title":"Albumin-binding lipid-aptamer conjugates for cancer immunoimaging and immunotherapy","volume":"65","author":"Tian","year":"2022","journal-title":"Sci. China Chem."}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961224001200?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961224001200?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T14:19:28Z","timestamp":1731766768000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961224001200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":41,"alternative-id":["S0142961224001200"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2024.122586","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Co-delivery of Plinabulin and Tirapazamine boosts anti-tumor efficacy by simultaneously destroying tumor blood vessels and killing tumor cells","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2024.122586","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"122586"}}